A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7vPnC in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 78 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-15.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of the immune response, as well as for non-inferiority and safety as compared to 7-valent Pneumococcal Conjugate Vaccine.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine
Biological: 7vPnC
0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series
Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: 1 Month after the infant series (7 Months of age)
Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the toddler dose (13 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the toddler dose (13 months of age)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose
Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: 1 month after the toddler dose (13 months of age)
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (2 months of age)
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (4 months of age)
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (6 months of age)
Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (12 months of age)
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (2 months of age)
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (4 months of age)
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (6 months of age)
Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after dose (12 months of age)
| Milestone | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Started | 489 | 488 | 489 | 246 |
| Vaccinated dose 1 | 486 | 484 | 485 | 244 |
| Vaccinated dose 2 | 455 | 447 | 455 | 228 |
| Vaccinated dose 3 | 442 | 435 | 438 | 225 |
| Completed | 435 | 427 | 428 | 218 |
| Not completed | 54 | 61 | 61 | 28 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Parent or legal guardian request | 18 | 29 | 34 | 14 |
| Withdrew: Lost to follow-up | 10 | 11 | 7 | 6 |
| Withdrew: Protocol violation | 16 | 8 | 6 | 3 |
| Withdrew: Failed to return | 5 | 4 | 4 | 2 |
| Withdrew: Investigator request | 4 | 3 | 3 | 2 |
| Withdrew: Other | 0 | 2 | 4 | 0 |
| Withdrew: Adverse event | 1 | 2 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 1 | 1 |
| Milestone | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Started | 435 | 427 | 427 | 218 |
| Completed | 415 | 397 | 408 | 208 |
| Not completed | 20 | 30 | 19 | 10 |
| Withdrew: Other | 0 | 1 | 1 | 1 |
| Withdrew: Parent or legal guardian request | 4 | 11 | 6 | 3 |
| Withdrew: Failed to return | 7 | 6 | 5 | 1 |
| Withdrew: Lost to follow-up | 5 | 5 | 5 | 2 |
| Withdrew: Protocol violation | 2 | 4 | 2 | 2 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 |
| Withdrew: Investigator request | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Milestone | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Started | 415 | 397 | 408 | 208 |
| Completed | 408 | 391 | 404 | 200 |
| Not completed | 7 | 6 | 4 | 8 |
| Withdrew: Lost to follow-up | 4 | 1 | 1 | 3 |
| Withdrew: Failed to return | 2 | 2 | 1 | 3 |
| Withdrew: Parent or legal guardian request | 0 | 3 | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| GMC mcg/mL | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) |
|---|---|---|---|
| Common serotypes - serotype 4 (n=411, 404, 398) | 1.33 (1.24 to 1.43) | 1.34 (1.25 to 1.44) | 1.75 (1.63 to 1.88) |
| Common serotypes - serotype 6B (n=409, 401, 396) | 2.89 (2.58 to 3.23) | 2.15 (1.91 to 2.42) | 2.54 (2.27 to 2.85) |
| Common serotypes - serotype 9V (n=411, 403, 396) | 1.05 (0.98 to 1.12) | 1.11 (1.04 to 1.19) | 1.11 (1.04 to 1.19) |
| Common serotypes - serotype 14 (n=398. 387, 387) | 4.97 (4.59 to 5.37) | 5.13 (4.70 to 5.59) | 5.18 (4.72 to 5.69) |
| Common serotypes - serotype 18C (n=413, 401, 398) | 1.30 (1.22 to 1.38) | 1.34 (1.24 to 1.44) | 1.48 (1.38 to 1.58) |
| Common serotypes - serotype 19F (n=408, 399, 398) | 1.85 (1.71 to 1.99) | 2.07 (1.92 to 2.24) | 2.59 (2.40 to 2.78) |
| Common serotypes - serotype 23F (n=411, 402, 399) | 1.24 (1.13 to 1.36) | 1.27 (1.15 to 1.40) | 1.03 (0.94 to 1.14) |
| Additional serotypes - serotype 1 (n=411, 403,395) | 1.62 (1.50 to 1.76) | 1.81 (1.66 to 1.98) | 1.91 (1.76 to 2.07) |
| Additional serotypes - serotype 3 (n=406, 391,393) | 0.52 (0.48 to 0.55) | 0.56 (0.52 to 0.61) | 0.61 (0.57 to 0.66) |
| Additional serotypes - serotype 5 (n=412, 402,393) | 1.35 (1.24 to 1.47) | 1.05 (0.96 to 1.14) | 1.35 (1.25 to 1.47) |
| Additional serotypes - serotype 6A (n=413,402,398) | 2.40 (2.21 to 2.61) | 2.10 (1.92 to 2.29) | 2.12 (1.96 to 2.30) |
| Additional serotypes - serotype 7F (n=412,401,397) | 2.54 (2.37 to 2.71) | 2.52 (2.35 to 2.70) | 2.67 (2.50 to 2.85) |
| Additional serotype - serotype 19A (n=411,403,397) | 1.85 (1.71 to 2.00) | 2.00 (1.85 to 2.16) | 1.88 (1.74 to 2.02) |
Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
| observed percentage of participants | Combined 13vPnC | 7vPnC |
|---|---|---|
| Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series | 98.4 (95.3 to 99.7) | 98.5 (95.6 to 99.7) |
Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
| observed percentage of participants | Combined 13vPnC | 7vPnC |
|---|---|---|
| Poliovirus type 1 (n=183, 187) | 100.0 (98.0 to 100.0) | 100.0 (98.0 to 100.0) |
| Poliovirus type 2 (n=181, 186) | 98.9 (96.1 to 99.9) | 99.5 (97.1 to 100.0) |
| Poliovirus type 3 (n=182, 186) | 100.0 (98.0 to 100.0) | 99.5 (97.1 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.
| observed percentage of participants | Combined 13vPnC | 7vPnC |
|---|---|---|
| Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series | 100.0 (97.6 to 100.0) | 100.0 (97.9 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| observed percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) |
|---|---|---|---|
| Common serotypes - serotype 4 (n=411, 404, 398) | 97.6 (95.6 to 98.8) | 95.5 (93.0 to 97.3) | 98.5 (96.7 to 99.4) |
| Common serotypes - serotype 6B (n=409, 401, 396) | 94.9 (92.3 to 96.8) | 89.5 (86.1 to 92.3) | 94.4 (91.7 to 96.5) |
| Common serotypes - serotype 9V (n=411, 403, 396) | 95.4 (92.9 to 97.2) | 95.5 (93.0 to 97.3) | 96.5 (94.1 to 98.1) |
| Common serotypes - serotype 14 (n=398, 387, 387) | 99.2 (97.8 to 99.8) | 99.0 (97.4 to 99.7) | 98.2 (96.3 to 99.3) |
| Common serotypes - serotype 18C (n=413, 401, 398) | 97.8 (95.9 to 99.0) | 95.8 (93.3 to 97.5) | 98.0 (96.1 to 99.1) |
| Common serotypes - serotype 19F (n=408, 399, 398) | 97.8 (95.9 to 99.0) | 97.5 (95.4 to 98.8) | 99.2 (97.8 to 99.8) |
| Common serotypes - serotype 23F (n=411, 402, 399) | 91.2 (88.1 to 93.8) | 88.1 (84.5 to 91.1) | 87.2 (83.5 to 90.3) |
| Additional serotypes - serotype 1 (n=411, 403,395) | 97.8 (95.9 to 99.0) | 97.0 (94.9 to 98.5) | 98.5 (96.7 to 99.4) |
| Additional serotypes - serotype 3 (n=406, 391,393) | 68.5 (63.7 to 73.0) | 72.4 (67.7 to 76.8) | 79.1 (74.8 to 83.0) |
| Additional serotypes - serotype 5 (n=412, 402,393) | 94.2 (91.5 to 96.2) | 90.3 (87.0 to 93.0) | 94.4 (91.6 to 96.5) |
| Additional serotypes - serotype 6A (n=413,402,398) | 98.1 (96.2 to 99.2) | 95.5 (93.0 to 97.3) | 98.2 (96.4 to 99.3) |
| Additional serotypes - serotype 7F (n=412,401,397) | 99.8 (98.7 to 100.0) | 99.0 (97.5 to 99.7) | 99.7 (98.6 to 100.0) |
| Additional serotype - serotype 19A (n=411,403,397) | 98.1 (96.2 to 99.2) | 99.0 (97.5 to 99.7) | 98.7 (97.1 to 99.6) |
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| observed percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) |
|---|---|---|---|
| Common serotypes - serotype 4 (n=364, 342, 355) | 99.2 (97.6 to 99.8) | 99.1 (97.5 to 99.8) | 100.0 (99.0 to 100.0) |
| Common serotypes - serotype 6B (n=368,341,357) | 100.0 (99.0 to 100.0) | 100.0 (98.9 to 100.0) | 100.0 (99.0 to 100.0) |
| Common serotypes - serotype 9V (n=368,342,357) | 99.7 (98.5 to 100.0) | 99.7 (98.4 to 100.0) | 99.2 (97.6 to 99.8) |
| Common serotypes - serotype 14 (n=366,344,358) | 100.0 (99.0 to 100.0) | 99.7 (98.4 to 100.0) | 100.0 (99.0 to 100.0) |
| Common serotypes - serotype 18C (n=362,341,354) | 98.9 (97.2 to 99.7) | 98.5 (96.6 to 99.5) | 99.4 (98.0 to 99.9) |
| Common serotypes - serotype 19F (n=362,342,353) | 98.3 (96.4 to 99.4) | 98.8 (97.0 to 99.7) | 99.4 (98.0 to 99.9) |
| Common serotypes - serotype 23F (n=362,340,353) | 99.4 (98.0 to 99.9) | 99.1 (97.4 to 99.8) | 98.3 (96.3 to 99.4) |
| Additional serotypes - serotype 1 (n=367,344,357) | 100.0 (99.0 to 100.0) | 99.1 (97.5 to 99.8) | 99.2 (97.6 to 99.8) |
| Additional serotypes - serotype 3 (n=366,343,356) | 83.6 (79.4 to 87.3) | 80.8 (76.2 to 84.8) | 88.5 (84.7 to 91.6) |
| Additional serotypes - serotype 5 (n=368,343,357) | 99.7 (98.5 to 100.0) | 99.4 (97.9 to 99.9) | 99.7 (98.4 to 100.0) |
| Additional serotypes - serotype 6A (n=366,342,355) | 100.0 (99.0 to 100.0) | 100.0 (98.9 to 100.0) | 99.7 (98.4 to 100.0) |
| Additional serotypes - serotype 7F (n=366,343,358) | 100.0 (99.0 to 100.0) | 99.4 (97.9 to 99.9) | 99.4 (98.0 to 99.9) |
| Additional serotype - serotype 19A (n=362,341,353) | 100.0 (99.0 to 100.0) | 100.0 (98.9 to 100.0) | 100.0 (99.0 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| observed percentage of participants | Combined 13vPnC |
|---|---|
| Common serotypes - serotype 4 (n=1213) | 70.7 (68.1 to 73.3) |
| Common serotypes - serotype 6B (n=1206) | 78.9 (76.4 to 81.1) |
| Common serotypes - serotype 9V (n=1210) | 55.7 (52.9 to 58.5) |
| Common serotypes - serotype 14 (n=1172) | 95.2 (93.8 to 96.4) |
| Common serotypes - serotype 18C (n=1212) | 68.7 (66.0 to 71.3) |
| Common serotypes - serotype 19F (n=1205) | 85.4 (83.3 to 87.3) |
| Common serotypes - serotype 23F (n=1212) | 60.1 (57.2 to 62.8) |
| Additional serotypes - serotype 1 (n=1209) | 75.2 (72.7 to 77.6) |
| Additional serotypes - serotype 3 (n=1190) | 21.3 (19.0 to 23.8) |
| Additional serotypes - serotype 5 (n=1207) | 60.3 (57.5 to 63.1) |
| Additional serotypes - serotype 6A (n=1213) | 85.1 (82.9 to 87.0) |
| Additional serotypes - serotype 7F (n=1210) | 92.8 (91.2 to 94.2) |
| Additional serotypes - serotype 19A (n=1211) | 80.8 (78.4 to 82.9) |
Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| observed percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) |
|---|---|---|---|
| Common serotypes - serotype 4 (n=364,342,355) | 86.0 (82.0 to 89.4) | 87.4 (83.4 to 90.7) | 92.7 (89.5 to 95.2) |
| Common serotypes - serotype 6B (n=368,341,357) | 99.5 (98.1 to 99.9) | 99.1 (97.5 to 99.8) | 99.7 (98.4 to 100.0) |
| Common serotypes - serotype 9V (n=368,342,357) | 80.7 (76.3 to 84.6) | 84.5 (80.2 to 88.2) | 85.4 (81.3 to 88.9) |
| Common serotypes - serotype 14 (n=366,344,358) | 98.6 (96.8 to 99.6) | 98.8 (97.0 to 99.7) | 98.3 (96.4 to 99.4) |
| Common serotypes - serotype 18C (n=362,341,354) | 79.6 (75.0 to 83.6) | 85.0 (80.8 to 88.7) | 89.5 (85.9 to 92.5) |
| Common serotypes - serotype 19F (n=362,342,353) | 94.5 (91.6 to 96.6) | 95.3 (92.5 to 97.3) | 97.7 (95.6 to 99.0) |
| Common serotypes - serotype 23F (n=362,340,353) | 91.7 (88.4 to 94.3) | 91.2 (87.6 to 94.0) | 89.8 (86.2 to 92.8) |
| Additional serotypes - serotype 1 (n=367,344,357) | 91.8 (88.5 to 94.4) | 91.0 (87.5 to 93.8) | 94.4 (91.5 to 96.5) |
| Additional serotypes - serotype 3 (n=366,343,356) | 32.0 (27.2 to 37.0) | 30.3 (25.5 to 35.5) | 36.8 (31.8 to 42.0) |
| Additional serotypes - serotype 5 (n=368,343,357) | 94.0 (91.1 to 96.2) | 91.0 (87.4 to 93.8) | 93.6 (90.5 to 95.9) |
| Additional serotypes - serotype 6A (n=366,342,355) | 99.2 (97.6 to 99.8) | 98.2 (96.2 to 99.4) | 99.2 (97.6 to 99.8) |
| Additional serotypes - serotype 7F (n=366,343,358) | 98.1 (96.1 to 99.2) | 96.2 (93.6 to 98.0) | 98.6 (96.8 to 99.5) |
| Additional serotype - serotype 19A (n=362,341,353) | 100.0 (99.0 to 100.0) | 99.4 (97.9 to 99.9) | 99.7 (98.4 to 100.0) |
Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| GMC mcg/mL | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) |
|---|---|---|---|
| Common serotypes - serotype 4 (n=364,342,355) | 2.29 (2.11 to 2.48) | 2.25 (2.07 to 2.44) | 3.06 (2.79 to 3.35) |
| Common serotypes - serotype 6B (n=368,341,357) | 11.14 (10.24 to 12.11) | 9.33 (8.55 to 10.19) | 9.92 (9.15 to 10.75) |
| Common serotypes - serotype 9V (n=368,342,357) | 1.91 (1.76 to 2.06) | 1.95 (1.80 to 2.10) | 1.99 (1.84 to 2.15) |
| Common serotypes - serotype 14 (n=366,344,358) | 6.61 (6.06 to 7.22) | 7.05 (6.42 to 7.74) | 6.91 (6.32 to 7.56) |
| Common serotypes - serotype 18C (n=362,341,354) | 1.95 (1.78 to 2.12) | 2.20 (2.01 to 2.41) | 2.48 (2.27 to 2.71) |
| Common serotypes - serotype 19F (n=362,342,353) | 4.51 (4.05 to 5.03) | 4.67 (4.23 to 5.14) | 6.51 (5.91 to 7.18) |
| Common serotypes - serotype 23F (n=362,340,353) | 3.35 (3.02 to 3.71) | 3.46 (3.14 to 3.82) | 3.10 (2.81 to 3.43) |
| Additional serotypes - serotype 1 (n=367,344,357) | 2.75 (2.53 to 2.99) | 2.95 (2.68 to 3.24) | 3.01 (2.75 to 3.30) |
| Additional serotypes - serotype 3 (n=366,343,356) | 0.75 (0.69 to 0.81) | 0.71 (0.65 to 0.77) | 0.80 (0.74 to 0.87) |
| Additional serotypes - serotype 5 (n=368,343,357) | 3.11 (2.87 to 3.37) | 2.63 (2.42 to 2.87) | 2.80 (2.60 to 3.02) |
| Additional serotypes - serotype 6A (n=366,342,355) | 7.52 (6.93 to 8.17) | 6.97 (6.41 to 7.59) | 6.83 (6.30 to 7.41) |
| Additional serotypes - serotype 7F (n=366,343,358) | 4.35 (4.01 to 4.72) | 4.24 (3.86 to 4.66) | 4.58 (4.21 to 4.98) |
| Additional serotype - serotype 19A (n=362,341,353) | 8.41 (7.73 to 9.14) | 8.32 (7.66 to 9.04) | 8.60 (7.91 to 9.36) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Tenderness: Any (n=420, 409, 400, 212) | 62.4 | 64.1 | 62.5 | 67.0 |
| Tenderness: Significant (n=348, 337, 345, 170) | 9.2 | 10.4 | 10.4 | 12.9 |
| Induration: Any (n=356, 347, 352, 176) | 16.6 | 19.6 | 19.3 | 18.2 |
| Induration: Mild (n=353, 344, 348, 173) | 14.7 | 16.9 | 15.5 | 16.2 |
| Induration: Moderate (n=338, 328, 340, 167) | 3.6 | 5.8 | 5.0 | 3.6 |
| Induration: Severe (n=333, 325, 335, 164) | 0.0 | 0.0 | 0.0 | 0.0 |
| Erythema: Any (n=355, 352, 360, 180) | 19.4 | 25.0 | 23.1 | 22.8 |
| Erythema: Mild (n=354, 352, 358, 180) | 18.1 | 24.7 | 21.2 | 21.7 |
| Erythema: Moderate (n=334, 326, 337, 164) | 2.1 | 0.6 | 2.4 | 1.2 |
| Erythema: Severe (n=333, 325, 335, 164) | 0.0 | 0.0 | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Tenderness: Any (n=354, 330, 337, 176) | 66.4 | 67.3 | 65.0 | 64.8 |
| Tenderness: Significant (n=269, 231, 262, 132) | 9.7 | 7.4 | 12.2 | 11.4 |
| Induration: Any (n=291, 248, 279, 141) | 24.4 | 22.6 | 28.7 | 17.7 |
| Induration: Mild (n=288, 246, 276, 141) | 22.6 | 22.0 | 26.8 | 17.7 |
| Induration: Moderate (n=270, 224, 255, 128) | 4.1 | 1.3 | 4.7 | 3.9 |
| Induration: Severe (n=263, 221, 250, 127) | 0.0 | 0.0 | 0.4 | 0.0 |
| Erythema: Any (n=292, 265, 281, 153) | 30.1 | 35.8 | 34.5 | 30.1 |
| Erythema: Mild (n=289, 263, 279, 153) | 28.4 | 34.6 | 33.3 | 28.8 |
| Erythema: Moderate (n=268, 223, 252, 128) | 3.4 | 1.8 | 3.2 | 3.1 |
| Erythema: Severe (n=263, 221, 249, 127) | 0.0 | 0.0 | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Tenderness: Any (n=317, 304, 300, 156) | 62.5 | 60.9 | 55.0 | 64.7 |
| Tenderness: Significant (n=248, 226, 237, 118) | 8.9 | 7.5 | 10.1 | 11.9 |
| Induration: Any (n=263, 250, 262, 128) | 27.0 | 23.6 | 28.6 | 30.5 |
| Induration: Mild (n=260, 249, 260, 127) | 24.6 | 22.5 | 27.3 | 29.1 |
| Induration: Moderate (n=242, 221, 229, 114) | 4.1 | 4.1 | 3.9 | 7.0 |
| Induration: Severe (n=237, 217, 227, 111) | 0.0 | 0.0 | 0.0 | 0.0 |
| Erythema: Any (n=278, 262, 274, 137) | 39.6 | 35.9 | 37.6 | 39.4 |
| Erythema: Mild (n=275, 260, 272, 135) | 37.1 | 33.8 | 36.4 | 38.5 |
| Erythema: Moderate (n=243, 219, 231, 116) | 5.3 | 4.1 | 5.6 | 7.8 |
| Erythema: Severe (n=237, 217, 227, 111) | 0.0 | 0.0 | 0.0 | 0.0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | Combined 13vPnC | 7vPnC |
|---|---|---|
| Tenderness: Any (n=826, 131) | 57.3 | 63.4 |
| Tenderness: Significant (n=630, 97) | 6.7 | 4.1 |
| Induration: Any (n=698, 110) | 31.5 | 43.6 |
| Induration: Mild (n=689, 107) | 28.9 | 41.1 |
| Induration: Moderate (n=627, 101) | 8.5 | 17.8 |
| Induration: Severe (n=603, 93) | 0.0 | 0.0 |
| Erythema: Any (n=749, 121) | 42.6 | 52.9 |
| Erythema: Mild (n=735, 116) | 39.2 | 50.0 |
| Erythema: Moderate (n=631, 104) | 10.6 | 21.2 |
| Erythema: Severe (n=603, 93) | 0.0 | 0.0 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Fever ≥38 but ≤39 degrees C (n=353, 337, 353, 173) | 24.6 | 23.4 | 24.6 | 26.0 |
| Fever >39 but ≤40 degrees C (n=328, 319, 333, 161) | 0.6 | 0.3 | 0.9 | 1.2 |
| Fever >40 degrees C (n=328, 319, 331, 160) | 0.0 | 0.0 | 0.3 | 0.6 |
| Decreased appetite (n=393, 385, 386, 200) | 50.6 | 46.0 | 50.0 | 49.0 |
| Irritability (n=435, 432, 433, 226) | 85.7 | 84.3 | 89.1 | 87.6 |
| Increased sleep (n=425, 417, 402, 212) | 71.5 | 72.7 | 69.4 | 72.6 |
| Decreased sleep (n=379, 377, 377, 194) | 44.1 | 46.9 | 42.2 | 46.4 |
| Hives [urticaria] (n=333, 328, 335, 164) | 0.6 | 0.9 | 0.6 | 0.0 |
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Fever ≥38 but ≤39 degrees C (n=290, 250, 290, 143) | 33.4 | 36.4 | 35.5 | 28.0 |
| Fever >39 but ≤40 degrees C (n=263, 216, 248, 124) | 3.4 | 3.2 | 3.6 | 0.0 |
| Fever >40 degrees C (n=259, 214, 245, 124) | 0.4 | 0.0 | 0.0 | 0.0 |
| Decreased appetite (n=322, 293, 325, 164) | 48.4 | 49.1 | 48.0 | 49.4 |
| Irritability (n=377, 370, 376, 201) | 86.5 | 86.5 | 84.6 | 81.1 |
| Increased sleep (n=332, 318, 343, 177) | 64.8 | 68.2 | 67.3 | 63.3 |
| Decreased sleep (n=324, 291, 305, 159) | 49.1 | 48.8 | 44.6 | 48.4 |
| Hives [urticaria] (n=263, 225, 253, 127) | 0.4 | 2.2 | 1.6 | 0.8 |
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC |
|---|---|---|---|---|
| Fever ≥38 but ≤39 degrees C (n=266, 246, 252, 132) | 26.3 | 27.6 | 31.7 | 32.6 |
| Fever >39 but ≤40 degrees C (n=237, 219, 231, 113) | 2.5 | 3.7 | 5.6 | 6.2 |
| Fever >40 degrees C (n=234, 216, 224, 111) | 0.0 | 0.5 | 0.0 | 0.9 |
| Decreased appetite (n=286, 273, 286, 144) | 45.8 | 48.0 | 50.7 | 50.0 |
| Irritability (n=352, 339, 347, 186) | 79.5 | 80.5 | 82.7 | 84.4 |
| Increased sleep (n=289, 289, 286, 138) | 55.4 | 58.8 | 59.8 | 51.4 |
| Decreased sleep (n=282, 272, 289, 147) | 42.6 | 50.4 | 48.4 | 56.5 |
| Hives [urticaria] (n=239, 218, 229, 112) | 1.7 | 0.9 | 1.7 | 1.8 |
Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | Combined 13vPnC | 7vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C (n=667, 107) | 28.8 | 29.9 |
| Fever >39 but ≤40 degrees C (n=592, 95) | 4.4 | 5.3 |
| Fever >40 degrees C (n=586, 93) | 1.0 | 0.0 |
| Decreased appetite (n=790, 115) | 51.9 | 50.4 |
| Irritability (n=943, 160) | 81.8 | 80.0 |
| Increased sleep (n=779, 126) | 47.8 | 47.6 |
| Decreased sleep (n=770, 117) | 46.9 | 42.7 |
| Hives [urticaria] (n=607, 96) | 2.1 | 5.2 |
Collected over Baseline through 6 Month Follow-up after last study vaccination (18 Months). Local reactions and systemic events assessed within 7 days of dose: Infant Series Dose 1, 2, and 3 at 2, 4, and 6 months of age, respectively; Toddler Dose at 12 months of age.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infant Series 13vPnC (Pilot Lot 1) | — | 13/486 (2.7%) | 407/486 (83.7%) |
| Infant Series 13vPnC (Pilot Lot 2) | — | 23/483 (4.8%) | 394/483 (81.6%) |
| Infant Series 13vPnC (Manufacturing Lot) | — | 17/483 (3.5%) | 402/483 (83.2%) |
| Infant Series 7vPnC | — | 15/244 (6.1%) | 207/244 (84.8%) |
| After the Infant Series Combined 13vPnC | — | 25/1,445 (1.7%) | 88/1,445 (6.1%) |
| After the Infant Series 7vPnC | — | 3/244 (1.2%) | 11/244 (4.5%) |
| Toddler Dose Combined 13vPnC | — | 9/1,210 (0.7%) | 771/1,210 (63.7%) |
| Toddler Dose 7vPnC | — | 1/208 (0.5%) | 128/208 (61.5%) |
| Post Toddler Dose 6-Month Follow-up Combined 13vPnC | — | 21/1,443 (1.5%) | 37/1,443 (2.6%) |
| Post Toddler Dose 6-Month Follow-up 7vPnC | — | 7/244 (2.9%) | 9/244 (3.7%) |
| Event | Infant Series 13vPnC (Pilot Lot 1) | Infant Series 13vPnC (Pilot Lot 2) | Infant Series 13vPnC (Manufacturing Lot) | Infant Series 7vPnC | After the Infant Series Combined 13vPnC | After the Infant Series 7vPnC | Toddler Dose Combined 13vPnC | Toddler Dose 7vPnC | Post Toddler Dose 6-Month Follow-up Combined 13vPnC | Post Toddler Dose 6-Month Follow-up 7vPnC |
|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus bronchiolitisInfections and infestations | 2/486 | 5/483 | 4/483 | 2/244 | 1/1445 | 0/244 | 0/1210 | 0/208 | 1/1443 | 0/244 |
| BronchiolitisInfections and infestations | 5/486 | 2/483 | 4/483 | 2/244 | 2/1445 | 0/244 | 0/1210 | 1/208 | 1/1443 | 0/244 |
| PyrexiaGeneral disorders | 0/486 | 3/483 | 0/483 | 2/244 | 1/1445 | 0/244 | 0/1210 | 0/208 | 0/1443 | 0/244 |
| PneumoniaInfections and infestations | 2/486 | 1/483 | 2/483 | 2/244 | 1/1445 | 1/244 | 0/1210 | 1/208 | 3/1443 | 1/244 |
| Urinary tract infectionInfections and infestations | 1/486 | 1/483 | 1/483 | 2/244 | 0/1445 | 0/244 | 1/1210 | 0/208 | 0/1443 | 0/244 |
| Otitis mediaInfections and infestations | 0/486 | 3/483 | 0/483 | 0/244 | 0/1445 | 0/244 | 0/1210 | 0/208 | 1/1443 | 2/244 |
| DehydrationMetabolism and nutrition disorders | 0/486 | 1/483 | 3/483 | 2/244 | 1/1445 | 0/244 | 1/1210 | 0/208 | 0/1443 | 1/244 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/486 | 0/483 | 0/483 | 0/244 | 0/1445 | 0/244 | 0/1210 | 0/208 | 4/1443 | 2/244 |
| Croup infectiousInfections and infestations | 0/486 | 3/483 | 0/483 | 1/244 | 0/1445 | 0/244 | 0/1210 | 0/208 | 1/1443 | 1/244 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/486 | 3/483 | 0/483 | 1/244 | 1/1445 | 0/244 | 0/1210 | 0/208 | 0/1443 | 0/244 |
| Event | Infant Series 13vPnC (Pilot Lot 1) | Infant Series 13vPnC (Pilot Lot 2) | Infant Series 13vPnC (Manufacturing Lot) | Infant Series 7vPnC | After the Infant Series Combined 13vPnC | After the Infant Series 7vPnC | Toddler Dose Combined 13vPnC | Toddler Dose 7vPnC | Post Toddler Dose 6-Month Follow-up Combined 13vPnC | Post Toddler Dose 6-Month Follow-up 7vPnC |
|---|---|---|---|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 373/435 | 364/432 | 386/433 | 198/226 | — | — | 771/943 | 128/160 | — | — |
| IrritabilityGeneral disorders | 326/377 | 320/370 | 318/376 | 163/201 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 280/352 | 273/339 | 287/347 | 157/186 | — | — | — | — | — | — |
| Increased sleepGeneral disorders | 304/425 | 303/417 | 279/402 | 154/212 | — | — | 372/779 | 60/126 | — | — |
| Increased sleepGeneral disorders | 215/332 | 217/318 | 231/343 | 112/177 | — | — | — | — | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 235/354 | 222/330 | 219/337 | 114/176 | — | — | — | — | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 262/420 | 262/409 | 250/400 | 142/212 | — | — | 473/826 | 83/131 | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 198/317 | 185/304 | 165/300 | 101/156 | — | — | — | — | — | — |
| Increased sleepGeneral disorders | 160/289 | 170/289 | 171/286 | 71/138 | — | — | — | — | — | — |
| Decreased sleepGeneral disorders | 120/282 | 137/272 | 140/289 | 83/147 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC | Total |
|---|---|---|---|---|---|
| Mean | 2.2 ± 0.3 | 2.2 ± 0.3 | 2.2 ± 0.3 | 2.2 ± 0.3 | 2.2 ± 0.3 |
| Sex/Gender, Customized(participants) | 13vPnC (Pilot Lot 1) | 13vPnC (Pilot Lot 2) | 13vPnC (Manufacturing Lot) | 7vPnC | Total |
|---|---|---|---|---|---|
| Female | 230 | 226 | 213 | 115 | 784 |
| Male | 259 | 260 | 275 | 131 | 925 |
| Unknown | 0 | 2 | 1 | 0 | 3 |
The record gives a start of May 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →